Status | Study |
Completed |
Study Name: A Phase II Study Of Imtox-25 In Adults With Refractory/Relapsed Cd25 Positive Adult T Cell Leukemia/Lymphoma Condition: Adult T Cell Leukemia Adult T Cell Lympho Date: 2011-05-12 Interventions: Drug: IMTOX-25 This agent is s |
Completed |
Study Name: Lenalidomide in HTLV-1 Adult T-Cell Leukemia Condition: Adult T Cell Leukemia/Lymphoma Date: 2011-01-10 Interventions: Drug: Lenalidomide 25mg or 10mg (based on creatinine clearance) once daily for days 1-21 of a 28 day cyc |
Completed |
Study Name: Multicenter, Randomized, Open-label, Parallel-group Study to Compare mLSG15 + KW-0761 to mLSG15 Condition: Adult T-cell Leukemia-Lymphoma Date: 2010-07-30 Interventions: Drug: VCAP/AMP/VECP(mLSG15) VC |
Completed |
Study Name: A Phase I, Multicenter, Open-label, Dose-escalation Study to Assess the Safety of Lenalidomide in Patients With Advanced Adult T-cell Leukemia-lymphoma and Peripheral T-cell Lymphomaperipheral T-cell Lymphoma Condition: Adult T-cell Leukemia-Lymphoma Peripheral T-cell Lymphoma Date: 2010-07-22 Interventions: Drug: Lenalidomide Lenalidomide: 25mg daily on day 1-21 of each 28days cycle (1st cohort), 25 mg daily o |
Completed |
Study Name: EPOCH Chemotherapy and Bortezomib for Associated T-Cell Leukemia Lymphoma Condition: Leukemia-Lymphoma, Adult T-Cell Date: 2009-10-19 Interventions: Drug: Bortezomib Other Name: V |
Active, not recruiting |
Study Name: Phase II Trial of LMB-2, Fludarabine and Cyclophosphamide for Adult T-Cell Leukemia Condition: Adult T-Cell Leukemia (ATL) Date: 2009-06-17 Interventions: Drug: LMB-2 Begin with 30 mcg/ |
Completed |
Study Name: Phase II Study of KW-0761 in Subjects With CCR4-positive Adult T-cell Leukemia-lymphoma Condition: Adult T-cell Leukemia-lymphoma Date: 2009-06-09 Interventions: Biological: KW-0761 KW-0761 is administered weekly for 8 weeks as an intravenous infusion of 2 hours at |
Terminated |
Study Name: Zidovudine, Interferon Alfa-2b, and PEG-Interferon Alfa-2b in Treating Patients With Human T-Cell Lymphotropic Virus Type 1-Associated Adult T-Cell Leukemia/Lymphoma Condition: Lymphoma Precancerous/Nonmalignant Condition Date: 2009-02-28 Interventions: Biological: PEG-interferon alfa-2b |
Terminated |
Study Name: Study of Oral LBH589 in Patients With Cutaneous T-cell Lymphoma and Adult T-cell Leukemia/Lymphoma Condition: Cutaneous T-Cell Lymphoma Leukemia-Lymphoma, Adult T-Cell Date: 2008-06-13 Interventions: Drug: Panobinostat (LBH589) 20mg/day p.o. on three times-a- week |
Completed |
Study Name: 506U78 In Relapsed Or Refractory Acute Lymphoblastic Leukemia (T-ALL) Condition: T-ALL, T-NHL (Lymphoblastic) Date: 2008-05-16 Interventions: Drug: Nelarabine 1500 mg/m² i.v., duration 2 hrs, day 1, 3, 5 |